Hantz Financial Services Inc. Sells 25,334 Shares of Smith & Nephew SNATS, Inc. $SNN

Posted by George Bondi on May 28th, 2026

Hantz Financial Services Inc. lessened its holdings in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN – Free Report) by 33.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 50,063 shares of the medical equipment provider’s stock after selling 25,334 shares during the quarter. Hantz Financial Services Inc.’s holdings in Smith & Nephew SNATS were worth $1,643,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Todd Asset Management LLC purchased a new stake in shares of Smith & Nephew SNATS in the third quarter worth about $26,319,000. Goldman Sachs Group Inc. lifted its holdings in shares of Smith & Nephew SNATS by 49.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock worth $50,255,000 after buying an additional 583,809 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Smith & Nephew SNATS by 139.9% in the third quarter. Bank of America Corp DE now owns 987,274 shares of the medical equipment provider’s stock worth $35,828,000 after buying an additional 575,666 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Smith & Nephew SNATS by 365.1% in the second quarter. BNP Paribas Financial Markets now owns 644,525 shares of the medical equipment provider’s stock worth $19,742,000 after buying an additional 505,934 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Smith & Nephew SNATS in the third quarter worth about $16,501,000. Institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Trading Down 0.9%

Shares of SNN opened at $30.16 on Thursday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.57 and a quick ratio of 1.25. The firm has a fifty day simple moving average of $31.75 and a two-hundred day simple moving average of $33.05. Smith & Nephew SNATS, Inc. has a twelve month low of $28.40 and a twelve month high of $38.79.

Smith & Nephew SNATS (NYSE:SNN – Get Free Report) last released its quarterly earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share for the quarter. The company had revenue of $1.60 billion during the quarter. As a group, equities analysts predict that Smith & Nephew SNATS, Inc. will post 2.25 earnings per share for the current fiscal year.

Smith & Nephew SNATS Dividend Announcement

The firm also recently announced a dividend, which was paid on Wednesday, May 27th. Stockholders of record on Friday, March 27th were issued a dividend of $0.482 per share. This represents a dividend yield of 304.0%. The ex-dividend date was Friday, March 27th.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Sanford C. Bernstein set a $31.85 target price on shares of Smith & Nephew SNATS in a research note on Monday, May 11th. Wall Street Zen downgraded shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Smith & Nephew SNATS in a research note on Monday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Monday, April 20th. Finally, Canaccord Genuity Group lowered their target price on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a research note on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Smith & Nephew SNATS has a consensus rating of “Moderate Buy” and an average price target of $30.93.

View Our Latest Stock Report on Smith & Nephew SNATS

About Smith & Nephew SNATS

(Free Report)

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.